Insider Selling: Cadrenal Therapeutics (NASDAQ:CVKD) CFO Sells $25,182.00 in Stock

Posted by Scott Moore on Oct 31st, 2025

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) CFO Matthew Szot sold 1,800 shares of Cadrenal Therapeutics stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $13.99, for a total transaction of $25,182.00. Following the completion of the transaction, the chief financial officer directly owned 9,933 shares in the company, valued at approximately $138,962.67. This trade represents a 15.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Cadrenal Therapeutics Price Performance

CVKD stock opened at $12.92 on Friday. The firm has a market capitalization of $26.49 million, a P/E ratio of -1.45 and a beta of 0.96. Cadrenal Therapeutics, Inc. has a 52-week low of $8.74 and a 52-week high of $22.90. The company’s 50 day simple moving average is $13.40 and its 200-day simple moving average is $13.47.

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($1.87) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.27). Sell-side analysts predict that Cadrenal Therapeutics, Inc. will post -7.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $32.00.

View Our Latest Stock Report on Cadrenal Therapeutics

About Cadrenal Therapeutics

(Get Free Report)

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.